Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 71335-2146

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 71335-2146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
This is a graph showing the mean change in IPSS total symptom score over time for two groups - placebo and those taking alfuzosin hydrochloride extended-release tablets, displayed across four time periods. The sample size for each group is shown in parentheses. The graph suggests that the alfuzosin group had a significant improvement in symptoms compared to the placebo group.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
The text describes a graph labeled as Figure 3 showing the mean change from Baseline in IPSS Total Symptom Score over 28 and 56 days of treatment using a placebo (N=152) and Alfuzosin hydrochloride extended-release tablets (N=137). The graph suggests a significant improvement in the total symptom score in the latter compared to the former.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
The text provides a figure (Figure 4) that shows the mean change from baseline in IPSS Total Symptom Score for Trial 3. It compares the results of a group of patients who received a placebo (N=150) with those who received Alfuzosin hydrochloride extended-release tablets (N=151) for 28 to 56 days. The figure suggests that the Alfuzosin hydrochloride treatment resulted in a statistically significant improvement in IPSS Total Symptom Score compared to the placebo group (p <0.01).*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
The text describes a graph presenting the mean change from baseline in peak urine flow rate (in mL/s) over a period of 56 days of treatment. The graph compares the results of a placebo group (N=167) and a group taking alfuzosin hydrochloride extended-release tablets (N=170). The graph shows a statistically significant improvement in peak urine flow rate in the group taking alfuzosin hydrochloride extended-release tablets compared to the placebo group.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
This is a chart that shows the mean change from baseline in peak urine flow rate (mL/s) for Trial 3, where three groups of participants were given different treatments for a period of 84 days. One group of 150 participants was given a Placebo, while another group of 151 participants was given 25 units of Alfuzosin hydrochloride extended-release tablets. The chart shows that there is no significant difference between the two groups, as indicated by the not significant (NS) p-value of greater than 0.05.*
FDA Label Image

Label (Lbl713352146)

Label (Lbl713352146)
This appears to be a description of a medication package, with information about the medication Uroxatral 10mg Tablet, the manufacturer Sun Pharmaceutical Industries Ltd., an expiration date, and storage instructions. It also includes a warning to keep all drugs out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.